Jan 16, 2012, 08.10 PM | Source: CNBC-TV18
Chairman of Mankind Pharma, Ramesh Juneja, tells CNBC-TV18 that they aim to enter the league of top five in the pharma space in the next three years and reach the top slot by 2016.
Archana Shukla (more)
Reporter, CNBC-TV18 |
Is this an ambitious or realistic vision? Going by its history, it could be realistic to some extent. Mankind Pharma is a closely held company that has almost doubled revenues every two years for six straight years to Rs 2,000 crores. They have followed the lowest drug pricing policy; their strategy has been to keep their prices low to push sales numbers and volumes in the Indian market. However, in a competitive market like the pharmaceutical space where a lot multinational companies come in, this aim could be ambitious.
Going forward, Juneja tells CNBC-TV18 that they plan to add another 1000 people to their workforce within two years. They currently have a field force of 6000 people. He further said that they intend to launch about 35 products every year for the next 2-3 years and are eyeing a growth of about 40-45% in the Indian market.
Watch the accompanying video for more details..
Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspection
Hold Torrent Pharma; target of Rs 1560: Religare
Religare has recommended hold rating on Torrent Ph
Buy Aurobindo Pharma;target of Rs 940: Axis Securities
Axis Securities is bullish on Aurobindo Pharma has
Sun Pharma Q3 beats estimates, profit jumps 28%; revenue up 3.6%
Revenue increased 3.6 percent to Rs 7,082 crore in
Buy Aurobindo Pharma; target of Rs 905: Emkay
Emkay is bullish on Aurobindo Pharma and has recom
Jenburkt Pharma standalone Dec '15 sales at Rs 24.20 crore
Jenburkt Pharma has reported a sales total income
Inside Chhattisgarh: The rise of industrialisation
CNBC TV18's Archana Shukla finds out that the ghos
Inside Chhattisgarh: What it means to live in a naxal-hit region
CNBC- TV18's Archana Shukla traveled to the heart